Compare Stocks: DSGN, IOVA, IDYA, and GMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$15.08 -1.1%	$13.90	$5.24 ▼ $17.25	$943.71M	1.63	578,970 shs	422,696 shs
GMTX Gemini Therapeutics	$82.55 -0.1%	$76.53	$1.16 ▼ $14.10	$3.58B	-0.12	189,291 shs	324,131 shs
IDYA IDEAYA Biosciences	$40.68 -2.6%	$36.99	$23.23 ▼ $42.68	$3.57B	-0.1	1.07 million shs	332,446 shs
IOVA Iovance Biotherapeutics	$8.01 -3.0%	$5.39	$1.76 ▼ $9.36	$3.63B	0.71	15.65 million shs	3.74 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	-2.18%	-1.99%	+28.48%	+45.52%	+188.28%
GMTX Gemini Therapeutics	+0.32%	+2.93%	+11.54%	+16.77%	+38.28%
IDYA IDEAYA Biosciences	+0.46%	+6.80%	+15.51%	+41.74%	+67.08%
IOVA Iovance Biotherapeutics	+2.23%	-8.12%	+75.74%	+101.46%	+241.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$15.08 -1.1%	$13.90	$5.24 ▼ $17.25	$943.71M	1.63	578,970 shs	422,696 shs
GMTX Gemini Therapeutics	$82.55 -0.1%	$76.53	$1.16 ▼ $14.10	$3.58B	-0.12	189,291 shs	324,131 shs
IDYA IDEAYA Biosciences	$40.68 -2.6%	$36.99	$23.23 ▼ $42.68	$3.57B	-0.1	1.07 million shs	332,446 shs
IOVA Iovance Biotherapeutics	$8.01 -3.0%	$5.39	$1.76 ▼ $9.36	$3.63B	0.71	15.65 million shs	3.74 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	-2.18%	-1.99%	+28.48%	+45.52%	+188.28%
GMTX Gemini Therapeutics	+0.32%	+2.93%	+11.54%	+16.77%	+38.28%
IDYA IDEAYA Biosciences	+0.46%	+6.80%	+15.51%	+41.74%	+67.08%
IOVA Iovance Biotherapeutics	+2.23%	-8.12%	+75.74%	+101.46%	+241.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	9.42% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IDYA IDEAYA Biosciences	2.81	Moderate Buy	$50.13	23.22% Upside
IOVA Iovance Biotherapeutics	2.45	Hold	$8.89	10.97% Upside

Current Analyst Ratings Breakdown

Latest DSGN, IOVA, IDYA, and GMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	IOVA Iovance Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $10.00
8/20/2026	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$4.00 ➝ $7.00
8/18/2026	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $11.00
8/7/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$6.00
8/7/2026	IOVA Iovance Biotherapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/7/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $13.00
8/7/2026	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$5.00 ➝ $8.00
8/5/2026	IDYA IDEAYA Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $60.00
8/5/2026	IDYA IDEAYA Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$63.00 ➝ $59.00
7/17/2026	DSGN Design Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IDYA IDEAYA Biosciences	$218.71M	16.34	N/A	N/A	$13.65 per share	2.98
IOVA Iovance Biotherapeutics	$263.50M	13.77	N/A	N/A	$1.62 per share	4.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)

Latest DSGN, IOVA, IDYA, and GMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$198.63 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	18.86	18.86
GMTX Gemini Therapeutics	N/A	71.49	71.49
IDYA IDEAYA Biosciences	N/A	10.45	10.45
IOVA Iovance Biotherapeutics	N/A	4.34	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
GMTX Gemini Therapeutics	75.42%
IDYA IDEAYA Biosciences	98.29%
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	17.10%
GMTX Gemini Therapeutics	12.90%
IDYA IDEAYA Biosciences	4.70%
IOVA Iovance Biotherapeutics	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IDYA IDEAYA Biosciences	80	87.86 million	83.73 million	Optionable
IOVA Iovance Biotherapeutics	500	452.97 million	417.64 million	Optionable

DSGN, IOVA, IDYA, and GMTX Headlines

Recent News About These Companies

What is Zacks Research's Estimate for IOVA Q3 Earnings?

August 28 at 7:11 AM | marketbeat.com

Palo Alto Investors LP Acquires Shares of 5,296,209 Iovance Biotherapeutics, Inc. $IOVA

August 28 at 6:31 AM | marketbeat.com

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

August 27 at 11:51 AM | zacks.com

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

August 27 at 5:31 AM | zacks.com

Ieq Capital LLC Invests $1.22 Million in Iovance Biotherapeutics, Inc. $IOVA

August 27 at 5:03 AM | marketbeat.com

Deutsche Bank AG Invests $3.56 Million in Iovance Biotherapeutics, Inc. $IOVA

August 27 at 3:37 AM | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $10.00

August 27 at 1:46 AM | americanbankingnews.com

5 Biotech Stocks Worth Adding to Your Portfolio Now

August 26 at 11:20 AM | zacks.com

ADAR1 Capital Management LLC Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

August 26 at 3:20 AM | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Upgraded at TD Cowen

August 25 at 6:59 AM | marketbeat.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Hold" by Brokerages

August 25 at 2:13 AM | marketbeat.com

Portland Investment Counsel Inc. Acquires Shares of 130,000 Iovance Biotherapeutics, Inc. $IOVA

August 24, 2026 | marketbeat.com

Iovance Biotherapeutics stock is trending Friday: What's going on?

August 22, 2026 | msn.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

August 21, 2026 | globenewswire.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8% - Here's Why

August 21, 2026 | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 11% Higher After Analyst Upgrade

August 21, 2026 | americanbankingnews.com

Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy

August 20, 2026 | zacks.com

Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates

August 20, 2026 | seekingalpha.com

Iovance Biotherapeutics (NASDAQ:IOVA) Marks Major Market Shift

August 20, 2026 | kalkinemedia.comK

Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month High - What's Next?

August 20, 2026 | marketbeat.com

Mizuho Increases Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $11.00

August 20, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, IOVA, IDYA, and GMTX Company Descriptions

Design Therapeutics NASDAQ:DSGN

$15.08 -0.17 (-1.11%)

As of 12:21 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Gemini Therapeutics NASDAQ:GMTX

$82.55 -0.12 (-0.15%)

As of 08/27/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

IDEAYA Biosciences NASDAQ:IDYA

$40.68 -1.09 (-2.61%)

As of 12:20 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Iovance Biotherapeutics NASDAQ:IOVA

$8.01 -0.25 (-3.03%)

As of 12:21 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, IOVA, IDYA, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, IOVA, IDYA, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, IOVA, IDYA, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, IOVA, IDYA, and GMTX Company Descriptions

Design Therapeutics NASDAQ:DSGN

Gemini Therapeutics NASDAQ:GMTX

IDEAYA Biosciences NASDAQ:IDYA

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, IOVA, IDYA, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, IOVA, IDYA, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, IOVA, IDYA, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, IOVA, IDYA, and GMTX Company Descriptions

Design Therapeutics NASDAQ:DSGN

Gemini Therapeutics NASDAQ:GMTX

IDEAYA Biosciences NASDAQ:IDYA

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools